Last reviewed · How we verify
D07001-Softgel Capsules
D07001-Softgel Capsules is a medication that works by inhibiting the reuptake of a specific neurotransmitter.
D07001-Softgel Capsules is a medication that works by inhibiting the reuptake of a specific neurotransmitter. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | D07001-Softgel Capsules |
|---|---|
| Sponsor | InnoPharmax Inc. |
| Drug class | Selective serotonin reuptake inhibitor |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This action results in increased levels of the neurotransmitter in the synaptic cleft, leading to its therapeutic effects. The exact mechanism of action is not fully understood, but it is believed to play a role in the treatment of certain conditions.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Fatigue
Key clinical trials
- Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer (PHASE2, PHASE3)
- D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer (PHASE3)
- Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |